Growth Metrics

Boston Scientific (BSX) Current Deferred Revenue (2019 - 2020)

Boston Scientific (BSX) has disclosed Current Deferred Revenue for 2 consecutive years, with $258.0 million as the latest value for Q3 2020.

  • Quarterly Current Deferred Revenue changed N/A to $258.0 million in Q3 2020 from the year-ago period, while the trailing twelve-month figure was $258.0 million through Sep 2020, changed N/A year-over-year, with the annual reading at $257.0 million for FY2019, N/A changed from the prior year.
  • Current Deferred Revenue hit $258.0 million in Q3 2020 for Boston Scientific, up from $251.0 million in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $258.0 million in Q3 2020 to a low of $141.0 million in Q1 2020.